BRPI0515794A - processes to evaluate patients with acute myeloid leukemia - Google Patents

processes to evaluate patients with acute myeloid leukemia

Info

Publication number
BRPI0515794A
BRPI0515794A BRPI0515794-3A BRPI0515794A BRPI0515794A BR PI0515794 A BRPI0515794 A BR PI0515794A BR PI0515794 A BRPI0515794 A BR PI0515794A BR PI0515794 A BRPI0515794 A BR PI0515794A
Authority
BR
Brazil
Prior art keywords
patient
processes
myeloid leukemia
therapy
acute myeloid
Prior art date
Application number
BRPI0515794-3A
Other languages
Portuguese (pt)
Inventor
Mitch Raponi
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of BRPI0515794A publication Critical patent/BRPI0515794A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

''PROCESSOS PARA AVALIAR PACIENTE COM LEUCEMIA MIELóIDE AGUDA ''.apresentação invenção refere-se a processos para o tratamento cãncer preferencialmente de expressã o genetica e/o de marcadores moleculares de um paciente paradeterminar o estado e/ou prognóstico do paciente .A invenção fornece ainda processos de análise se um paciente náo reflátario provavelmente responde ao tratamento co inihidores (FTIS) e; opcionalmente ; outros agentes terapêuticos .Os processos tanbém são úteis para monitorar a terapia do paciente e para selecionar um curso de terapia .São fornecidos genes modulados em respostas ao tratamento com FTI esão utilizados na formulação dos perfis.Methods for Evaluating Acute Myeloid Leukemia Patient. The present invention relates to methods for treating cancer preferentially of a patient's genetic expression and / or molecular markers to determine the patient's condition and / or prognosis. It also provides analysis processes if a non-reflective patient is likely to respond to consumer therapy (FTIS) and; optionally; other therapeutic agents .The processes are also useful for monitoring patient therapy and for selecting a course of therapy. Modulated genes are provided in response to FTI treatment and are used in profiling.

BRPI0515794-3A 2004-12-17 2005-12-19 processes to evaluate patients with acute myeloid leukemia BRPI0515794A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63726504P 2004-12-17 2004-12-17
US67011605P 2005-04-11 2005-04-11
US74118005P 2005-12-01 2005-12-01
PCT/US2005/046100 WO2006066240A2 (en) 2004-12-17 2005-12-19 Methods for assessing patients with acute myeloid leukemia

Publications (1)

Publication Number Publication Date
BRPI0515794A true BRPI0515794A (en) 2008-08-05

Family

ID=36588648

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515794-3A BRPI0515794A (en) 2004-12-17 2005-12-19 processes to evaluate patients with acute myeloid leukemia

Country Status (9)

Country Link
EP (1) EP1836313A4 (en)
JP (1) JP2008523822A (en)
KR (1) KR20070099564A (en)
AU (1) AU2005316291A1 (en)
BR (1) BRPI0515794A (en)
CA (1) CA2589055A1 (en)
IL (1) IL183555A0 (en)
MX (1) MX2007007401A (en)
WO (1) WO2006066240A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100617467B1 (en) * 2005-09-27 2006-09-01 디지탈 지노믹스(주) Markers for predicting the response of a patient with acute myeloid leukemia to anti-cancer drugs
CN103555825B (en) * 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 For the method and composition based on microRNA of the diagnosis of acute myelocytic leukemia (AML), prognosis and treatment
EP2056110A1 (en) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
EP2272028A1 (en) * 2008-04-25 2011-01-12 Koninklijke Philips Electronics N.V. Classification of sample data
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012007783A1 (en) * 2010-07-13 2012-01-19 Institut Gustave Roussy Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
WO2011131246A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
KR101660322B1 (en) * 2011-04-28 2016-09-29 아크레이 가부시키가이샤 Probe for detecting mutation in exon12 of npm1 gene and use thereof
KR101922761B1 (en) * 2015-11-18 2018-11-27 가톨릭대학교 산학협력단 A Real-time Quantitative PCR Analysis for the c-Kit mutant detection to Diagnose an Acute Myeloid Leukaemia and the Use thereof

Also Published As

Publication number Publication date
CA2589055A1 (en) 2006-06-22
WO2006066240A8 (en) 2006-09-08
EP1836313A4 (en) 2010-06-30
WO2006066240A3 (en) 2008-07-17
KR20070099564A (en) 2007-10-09
IL183555A0 (en) 2007-09-20
AU2005316291A1 (en) 2006-06-22
EP1836313A2 (en) 2007-09-26
WO2006066240A2 (en) 2006-06-22
JP2008523822A (en) 2008-07-10
MX2007007401A (en) 2007-10-08

Similar Documents

Publication Publication Date Title
BRPI0515794A (en) processes to evaluate patients with acute myeloid leukemia
BRPI0503418A (en) prognosis for hematologic malignancy
Murray et al. Tumor angiogenesis as a prognostic factor in laryngeal cancer
ATE486281T1 (en) PATIENT CLASSIFICATION
ATE353974T1 (en) METHODS, COMPOSITIONS AND KITS FOR IDENTIFYING AND MONITORING BREAST CANCER
ATE540319T1 (en) METHOD FOR DETERMINATION OF FK506
DE60228684D1 (en) SYSTEM FOR MONITORING THE CONCENTRATION OF ANALYTES IN BODY FLUIDS
DE69737788D1 (en) REAGENTS AND METHODS FOR DETECTING CHEST DISORDERS
DE60233949D1 (en) DIAGNOSTIC MARKERS FOR STROKE AND HARNTRAUMA AND METHOD OF USE THEREOF
CY1108829T1 (en) ACE2 Activation for Cardiac, Pulmonary and Renal Disease and Hypertension Therapy
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
CY1110076T1 (en) METHOD FOR DETERMINING CHK1 SUSPENSIONS
DE60222590D1 (en) METHODS FOR DETERMINING ACUTE MYELOUS LEUKEMIA
DK1816214T3 (en) Methods and compositions for perioperative genomic profiling
ATE426162T1 (en) METHOD FOR EXAMINING BODY FLOWS ON CANCER CELLS AND CORRESPONDING ANALYSIS KITS
CY1105566T1 (en) QUANTITATIVE DIAGNOSTIC ANALYSIS OF PREDISPOSITION TO HYPERTENSION
MXPA05014220A (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets.
DE60218843D1 (en) METHOD FOR IDENTIFYING MEDICAMENTS FOR THE TREATMENT OF DIABETES
Cheng et al. Cysteine cathepsin C: a novel potential biomarker for the diagnosis and prognosis of glioma
DE60044350D1 (en) PROSTATE SPECIFIC GEN PCGEM1 AND METHODS OF USE FOR THE RECOGNITION, TREATMENT AND PREVENTION OF PROSTATE CANCER
ATE449323T1 (en) REAGENTS AND METHODS USED FOR DETECTING BREAST DISEASES
BRPI0403291A (en) Cancer Assessment and Treatment Methods
WO1999014242A3 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
BR0115728A (en) Analysis of expression of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer.
ATE498020T1 (en) 5T4 RNA IN PLASMA AND SERUM AS A MARKER FOR NEOPLASTIC DISEASES

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.